Why trade high security for high performance when you can get both? Concrete Vaults deploy BitGo custody to execute automated compounding strategies for all your ctAssets. 🔋 https://t.co/TiXn21mRPO
1/ For years, qualified custody meant idle capital.
Today, that changes.
We're partnering with @BitGo to build a custody-native vault platform; institutional assets staying in regulated custody while running strategies through Concrete's vault architecture.
🌊 Let the wave of automation carry your capital further. Concrete Vaults optimize onchain capital deployment, ensuring that your capital efficiency is always backed by automated compounding. https://t.co/rhRDLSjan2
Bridges enable cross-chain activity but concentrate risk. Engineered trust manages these points with visibility and control. Explore Concrete at https://t.co/rhRDLSjan2
Thanks @FounderEric and the @FoundersBeta team for putting AllScale on the Top 100 Companies to Watch in 2026.
Still the only self-custody stablecoin neobank. Heads down on what's next.
Every market shift creates new challenges.
Only adaptive strategies can respond effectively.
Sustainable yield depends on flexibility.
Explore: https://t.co/kylmSuanV6
Costs play a major role in determining yield. Gas, slippage, and rebalancing can reduce returns over time. Focusing on net performance provides a clearer view of results.
Explore Concrete at https://t.co/DjbYOf4pIJ
looking at this @BioProtocol week and damn, the momentum's hitting different rn
Maelstrom Fund dropping $6.9M into the ecosystem signals institutional veins opening up into DeSci that kinda capital reweights the odds quickly, like when TradBio gets a wake-up call
launchpad action = wild
• $BiomeAI 6.4x oversubscribed
• $eDMT 4.2x oversubscribed
• 5M+ $BIO pledged, 6.1k+ ppl in the pool
but the part i'm actually staring at? the lending + Aave integration convo that moves DeSci from speculation into infrastructure. lending markets give liquidity to research, let teams runway experiments without begging a grant committee, and create yield pathways for tokenized IP
also: BioAgent Aubrai pulling ~$275k/mo in research funding = practical traction, not just PR flex. lowkey this separates builders from hype-chasers
quick thread in one tweet:
► XP = access. XP rules the front row for Ignition Sales
► Anti-dump mechanics (sell >50% = bio xp jail) align incentives
► tokenized IP + AI co-scientists shorten discovery loops
► institutional capital + on-chain funding = faster decision cadence
short-term: expect volatility at TGEs. long-term: networked funding + verifiable on-chain experiments compress timelines for real breakthroughs
if you��re stacking XP or watching allocations, keep focus on teams delivering experiments, not just liquidity events that’s where outsized upside compounds
DeSci tipping point feels real watch how capital + tooling rewires biotech funding and discovery paths worth watching